fbpx

QQQ
+ 2.31
364.32
+ 0.63%
BTC/USD
-984.87
60687.55
-1.6%
DIA
+ 3.70
345.43
+ 1.06%
SPY
+ 3.26
439.24
+ 0.74%
TLT
-0.85
146.73
-0.58%
GLD
-2.66
170.66
-1.58%

Organigram On Pace To Beat Tilray And Hexo In QoQ Sales Growth As Canadian Rec. Sales Reach $275.6M

September 7, 2021 8:15 am
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More
Organigram On Pace To Beat Tilray And Hexo In QoQ Sales Growth As Canadian Rec. Sales Reach $275.6M

As COVID-related restrictions begin to ease across the globe, some industries are feeling the benefits more than others. When it comes to Canadian recreational cannabis sales, new Hifyre scanner data reveals a 10% improvement sequentially, noted Cantor Fitzgerald’s Pablo Zuanic in his latest industry report.

The analyst was projecting more of an accelerated growth rate compared to the second-quarter growth pace, but that didn’t happen despite cannabis shops now receiving in-store traffic.

Hifyre estimated August sales reached CA$347 million ($275.6 million), representing

2% month-over-month growth, after hitting CA$339 million in July (which was up 7% from June). The average monthly sales for both months amount to CA$343 million, which is 10% higher than the second quarter monthly average, explained Zuanic.

“If we assumed September is flat month-over-month, this would still imply about 11% sequential quarter-over-quarter growth,” the analyst detailed, adding that this is neither good nor bad, just not “accelerated” as he was expecting.

The report also revealed that pre-rolls have driven growth accounting for 24% of sales, improving 27% over the second quarter monthly average. Flower sales were up only 2%, accounting for almost half of the sales, while vapes (13% of sales) and edibles (5% of sales) jumped 9% and 20%, respectively. Concentrates sales improved 24% and accounted for 4% of industry sales.

Performance By Company

Industry giants had various performances, with Organigram (NASDAQ: OGI) and Auxly 

(OTCQX: CBWTF) standing out and outperforming with 30% and 22%, respectively, Zuanic highlighted.

  • Cronos Group (NASDAQ: CRON) – Up 50%
  • Organigram – Up 30%;
  • Auxly – Up 22%;
  • Tilray (NASDAQ: TLRY) – Up 6%;
  • HEXO (NASDAQ: HEXO) – Up 7%;
  • Village Farms Intl (NASDAQ: VFF) – Up 7%;
  • Canopy Growth (NASDAQ: CGC) – Down 12% ;
  • Aurora Cannabis (NASDA: ACB) – Down 16%;
  • Sundial Growers ( NASDAQ: SNDL) – Down 4%.

“In terms of companies reporting July or August quarters, we calculate Organigram is on pace for a significant beat with August quarter sales up 44% sequentially, while HEXO (July quarter) and Tilray (August) point to low single-digit pro forma growth,” noted Zuanic.

Market Share By Company 

  • Tilray – 15.3% share (consisting of Aphria’s 11.1% and Tilray’s 4.2%);
  • HEXO (including Hexo and recently acquired Redecan, Zenabis and 48North) – 12.7% share;
  • Canopy Growth (counting Supreme) – 10.2% share;
  • Organigram – 7.1% share;
  • Village Farms Intl – 7.0% share;
  • Auxly – 5.3% share;
  • Cronos Group – 4.2% share;
  • Aurora Cannabis – 3.9% share;
  • Sundial Growers – 1.9% share. 

Price Action 

Organigram’s shares were trading 0.75% lower at $2.63 per share during Tuesday's pre-market session. 

Photo: Courtesy of Visual Stories || Micheile on Unsplash

For the latest in financial news, exclusive stories, memes follow Benzinga on Twitter, Facebook & Instagram. For the best interviews, stock market talk & videos, subscribe to Benzinga Podcasts and our YouTube channel.


Related Articles

Is Aurora Cannabis' 'Business Transformation Plan' Yielding Results?

Is Aurora Cannabis' 'Business Transformation Plan' Yielding Results?

Aurora Cannabis (NASDAQ: ACB) (TSX: ACB) reported a 45% year-over-year plunge in consumer cannabis net revenue, while its total net revenue in the fourth quarte read more
Will Aurora Become A Global Medical Marijuana Leader? Analyst Opines Ahead Of Q4 Earnings

Will Aurora Become A Global Medical Marijuana Leader? Analyst Opines Ahead Of Q4 Earnings

Canadian cannabis giant Aurora Cannabis Inc. (NYSE: ACB) (TSX: ACB) reported a plunge in third-quarter sales months ago, in addition to a negative adjusted EBITDA of CA$24 million ($28.3 million). read more
Tilray, Aurora, Sundial, Hexo Q2 Market And Sales Trends, Cantor Fitzgerald Projects Stronger Q3

Tilray, Aurora, Sundial, Hexo Q2 Market And Sales Trends, Cantor Fitzgerald Projects Stronger Q3

As COVID-19 safety measures begin to slowly lift and more people are getting vaccinated, many industries are beginning to blossom. For the cannabis industry, in particular, this could mean an improved third quarter (compared to the second quarter) as restrictions began to ease in June, according to Cantor Fitzgerald’s Pablo Zuanic. read more
Cantor Fitzgerald's Cannabis Conference: A Recap For Investors

Cantor Fitzgerald's Cannabis Conference: A Recap For Investors

Last week, Cantor Fitzgerald hosted CEOs from 14 Canadian legal cannabis producers as part of its Cannabis Forum. The Canadian cannabis market has many tailwinds, including post-pandemic store reopenings, understocked inventories, favorable regulatory changes and industry consolidation, the firm's analyst Pablo Zuanic said in a note.  read more